MMV (http://www.MMV.org) and
The WHO Guidelines for the Treatment of Malaria are the standard reference that guides country-level policies for the management of malaria. New drugs are recommended for inclusion only after a robust and thorough assessment of the evidence using the GRADE (http://bit.ly/3XuGnSy) framework, which is a systematic approach to clinical practice recommendations. provides perspective. Following this review – which included the largest clinical study to evaluate the real-world efficacy and safety of any anti-malarial – the guideline development committee formalized Pyramax into guidelines with a “strong” recommendation. Recommended to include – highest level of confidence.
Piramax is a fixed-dose artemisinin-based combination therapy (ACT) and is the only one specifically indicated for the blood-stage treatment of the two major species of malaria parasite: P. falciparum and P. vivax. This medicine is also available in a child-friendly granule formulation to ensure palatability and hence correct dosage in this vulnerable population.
Received both Pyramax Tablets and Pyramax Granules
Both formulations are currently registered in 29 countries for the treatment of uncomplicated malaria.
Following positive scientific opinion for use, a large cohort event monitoring study was implemented in 5 African countries Under the supervision of the CANTAM network To evaluate the safety and effectiveness of Pyramax under conditions similar to everyday clinical practice. This study, which reported high effectiveness (D28 PCR-adjusted cure rate of 98.6%), included more than 8,500 acute malaria episodes in 7,154 patients, and has recently been published in PLoS Medicine. ,
Pyramax was included in the WHO’s List of Pre-eligible Medicines in 2012 and the WHO’s List of Essential Medicines in 2017 for both adults and children. Pyramax has subsequently received a positive WHO review
after this review
“The official inclusion of Pyramax in the WHO Guidelines for Malaria is an important step, allowing malaria endemic countries to confidently select Pyramax as a first-line act. The managerial decision to initiate the Pyramax project was made by Shin Pong was based on the core values and company policies that have guided us for more than half a century. We will continue to produce qualified products to provide patients with powerful, reliable, simple treatments.”
 For more information about Cantum, please visit: http://bit.ly/3GGf9CE
 To read the Cantum study, please visit: http://bit.ly/3u4n6tD
for more information:
Phone +41 79 709 59 92
E-mail: [email protected]
Associate Director of Communications, MMV
Phone +41 79 896 20 61
E-mail: [email protected]
Background on Malaria Burden
According to the latest World Malaria Report (http://bit.ly/3EIJPRg), released on
In 2020, six countries accounted for more than half of all malaria deaths worldwide:
a fixed-dose combination of Pyramax, pinoridine and artesunate and the latest ACT combination approved by a
This once-daily, 3-day therapy is indicated for the treatment of acute malaria in adults and children over 20 kg (Piramax® Tablets) and in children and infants between 5 and 20 kg (Piramax® Granules).
About Article 58
Article 58 of Regulation (EC) No. 726/2004 establishes a mechanism whereby
Article 58 of the regulation responds to the need to protect and promote public health and to give scientific assistance in the context of cooperation to non-EU countries.
Shin Pong was established in 1962 with the headquarter located at
‘For the health of the people’ is the inspired corporate philosophy of the company. Shin Pong contributed extensively in eradicating parasitic diseases
Shin Pong Reach Public Development Partnership to work with its partners to deliver a healthcare model to end the global epidemic of infectious diseases and end-to-end execution from early detection for endemic infections to field implementation was in the lead.
For more information, please visit http://bit.ly/3OOIY6d
MMV is a major Product Development Partnership (PDP) in the area of anti-malarial drug research and development. Its mission is to reduce the burden of malaria in endemic countries by facilitating the discovery, development and distribution of new, effective and affordable anti-malarial drugs.
MMV receives funding and support from government agencies, private foundations, international organizations, corporations, corporate foundations, and private individuals. These funds are used to finance MMV’s portfolio of R&D projects as well as specific, targeted access and product management (APM) interventions aimed at increasing access to malaria drugs by vulnerable populations in endemic countries and to support their proper use.
Since its foundation in 1999, MMV and partners have built the largest portfolio of antimalarial R&D and access projects ever assembled and have advanced 15 new drugs. Nearly 3 million lives have been saved by these MMV co-developed drugs. MMV’s success is based on its extensive partnership network of approximately 150 active partners, including those from the pharmaceutical industry, academia and endemic countries.
MMV’s vision is a world in which innovative medicines will treat and protect vulnerable and underserved populations at risk of malaria, and ultimately help eliminate this terrible disease.
For more information, visit http://www.MMV.org
This document contains certain forward-looking statements that can be identified by words such as ‘believes’, ‘expects’, ‘estimates’, ‘projects’, ‘intends’, ‘should’, ‘expects’, ‘estimates’, ‘future’ Is. ‘ or similar expressions, or by discussion of vision, strategy, goals, plans, or intentions, among other things. This includes hypothetical future product target profiles, development timelines and approval/launch dates, positioning statements, claims and actions for which relevant data may still need to be established. The stated or implied strategies and action items may be implemented subject to approval, including, but not limited to, local Institutional Review Board approval, local regulatory approval, and compliance with local laws and regulations. Thus, actual results, performance or events may differ materially from those expressed or implied by such statements.
We ask you not to place undue reliance on these statements. Such forward-looking statements reflect the current views of
MMV accepts no liability for the information presented herein, nor for the consequences of any actions taken based on this information. Furthermore, MMV accepts no liability for the decisions made by its pharmaceutical partner(s), the effect of any of their decisions, their earnings and their financial condition.
© African Press Organisation, source